Pharmaceutical Commerce October 2026

Mike Hennessy Jr. on the commercial assumptions being rewritten across pricing, patient engagement and supply chain in PC's October 2026 print issue.

Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.

Ed Schoonveld examines the uncertainty surrounding President Trump's MFN drug pricing agreements, stalled GENEROUS, GLOBE and GUARD proposals, and their ripple effects on ex-US drug launches.

AI-native operating systems present new capabilities to improve pharma supply chain operations.

Pharmacy directors are using the growing number of publicly visible drug prices as leverage, new research shows. Manufacturers need to be ready, before those prices become a negotiation tool.

Virtual care's pre- and postvisit windows offer pharma marketers a more targeted, attentive audience than physical waiting rooms, new research shows, and most brands aren't capitalizing on it yet.

Health care's real challenge isn't more data, it's activation. Arcadia's Sandy Leonard on turning real-world evidence into point-of-care action.

Separating the combination MMR shot into three vaccines would not just change how children are immunized. It would require building three new supply chains from a licensing base that does not yet exist.

Access leaders are pressed to prove AI ROI, but ConnectiveRx execs Cindy Baksh and Steve Randall argue the real work is defining "better" first, then deciding where AI fits.

RxLogic's Ann Beal on how PBM reform indirectly impacts pharma manufacturers' affordability programs, rebate planning, and patient access.